Gilead Sciences, Inc. vs MasTec Inc — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B), while MasTec Inc trades at $277.54 (market cap $21.90B). The key difference: Gilead Sciences, Inc. is far larger — about 7.7× MasTec Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| GILD | MTZ | |
|---|---|---|
Market Cap | $168.35B | $21.90B |
Sector | Health | Technology |
52-Week High | $155.80 | $437.51 |
52-Week Low | $110.56 | $172.51 |
Enterprise Value | $191.42B | $24.81B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →